Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-15

FDA Approved: DALFAMPRIDINE — Supplemental Application (Ascend Laboratories, LLC)

View source ↗

Summary

FDA approved Ascend Laboratories, LLC's supplemental application for dalfampridine, resulting in a generic dalfampridine product being approved via ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalfampridine (dalfampridine)

Snippet

SUPPL AP for DALFAMPRIDINE (DALFAMPRIDINE)